Korean J Schizophr Res.
2013 Apr;16(1):14-24. 10.16946/kjsr.2013.16.1.14.
The Preference Survey for Long-Acting Injectable Antipsychotics of Community-Dwelling Patients with Schizophrenia and their Caregivers
- Affiliations
-
- 1Department of Neuropsychiatry and Institute of Clinical Psychopharmacology, Dongguk University International Hospital, Goyang, Korea. ciw@duih.org
- 2St. Andrew's Neuropsychiatric Hospital, Icheon, Korea.
- KMID: 2288300
- DOI: http://doi.org/10.16946/kjsr.2013.16.1.14
Abstract
OBJECTIVE
The prescription rates of long-acting injectable (LAI) antipsychotics are very low around 1% in Korea. This study was aimed to explore the preference of LAIs in patients with schizophrenia, who are currently living in community, and their caregivers.
METHODS
The patients, diagnosed with schizophrenia by DSM-IV TR and were registered in the 31 mental health centers of Gyeonggi province and their caregivers were inquired the knowledge of the LAIs. The questionnaires contained information such as demographic characteristics, history of psychiatric treatment, and so on.
RESULTS
About 5,318 were registered in 31 community mental health centers of Gyeonggi province in February 2012. The questionnaires of 614 patients and 365 caregivers were gathered from 20 community mental health centers. The mean ages (+/-SD) of patients and caregivers were 41.9 (+/-10.2) and 62.2 (+/-13.4) years old, respectively. 272 patients (44.6%) had experienced the discontinuation of medications without doctor's consent. 217 patients (35.9%) and 97 caregivers (27.1%) knew about the LAIs. The preference rates for LAIs were 35.2% and 46.8% for the patients and caregivers, respectively.
CONCLUSION
There is still huge discrepancy between the preference and the real prescriptions of LAIs in community-dwelling patients and their caregivers, much higher than in those of hospital settings. This study suggests that both patients and caregivers registered in the community mental health centers have a strong commitment to live in the community. The obstacles against the benefits of LAIs need to be resolved.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Combining Three Long-acting Injectable Antipsychotics: A Case Series
- Long-acting Injectable Antipsychotics in First-episode Schizophrenia
- Effectiveness of Aripiprazole Long-Acting Injection in Schizophrenia Patients Undergoing Antipsychotic Combination Therapy: A Retrospective Observational Study
- The Long-Acting Injectable Antipsychotics in Clinical Practice
- A Case of Aggressive and Violent Patient with Treatment-Resistant Schizophrenia Treated with Long-Acting Injectable Risperidone
